Everhart Financial Group Inc. Purchases 5,184 Shares of Cencora, Inc. $COR

Everhart Financial Group Inc. raised its position in shares of Cencora, Inc. (NYSE:COR) by 130.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,170 shares of the company’s stock after purchasing an additional 5,184 shares during the period. Everhart Financial Group Inc.’s holdings in Cencora were worth $2,753,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. BlackRock Inc. bought a new stake in Cencora in the second quarter worth approximately $5,154,136,000. T. Rowe Price Investment Management Inc. grew its stake in Cencora by 160.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after buying an additional 4,123,795 shares during the last quarter. Bank of America Corp DE grew its position in shares of Cencora by 6.9% in the first quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock valued at $1,300,033,000 after purchasing an additional 267,318 shares during the last quarter. Amundi lifted its position in shares of Cencora by 43.5% during the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock worth $630,855,000 after purchasing an additional 676,066 shares during the last quarter. Finally, Carmignac Gestion lifted its position in shares of Cencora by 58.7% during the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock worth $494,463,000 after purchasing an additional 646,112 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE COR traded up $2.21 during trading on Thursday, reaching $319.46. The company had a trading volume of 283,955 shares, compared to its average volume of 1,479,787. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The stock has a market cap of $60.96 billion, a PE ratio of 23.72, a PEG ratio of 1.62 and a beta of 0.58. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The business’s 50 day moving average price is $318.08 and its 200-day moving average price is $302.75.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, beating the consensus estimate of $4.35 by $0.13. The business had revenue of $84.75 billion for the quarter, compared to analysts’ expectations of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.00 earnings per share. Analysts expect that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, August 14th. Cencora’s dividend payout ratio (DPR) is 17.83%.

Analyst Ratings Changes

Several brokerages have commented on COR. Wells Fargo & Company lifted their price target on Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Citigroup reaffirmed a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Finally, Leerink Partners increased their target price on shares of Cencora from $380.00 to $388.00 and gave the company an “outperform” rating in a research note on Wednesday. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $372.07.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.38% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.